

Special Issue

Recent Advances in Brain Vascular Diseases Management and Therapy 2.0

Message from the Guest Editor

During the past several years, there has been increasing interest in the role of human cerebrovasculature and the blood-brain barrier (BBB) as etiological factors contributing to the development of seizures and chronic epilepsy. Recently, much emphasis has been placed on dysregulated angiogenesis, BBB permeability, and epilepsy. This Special Issue of *Biomedicines* will provide up-to-date information on different aspects of brain aging from the latest developments in the field of neurodegenerative disorders to cerebral microvascular mechanisms of cognitive decline. New avenues for research targeting cellular senescence, epigenetics, and endocrine mechanisms of brain aging are also discussed. This Special Issue will also cover recent advances in brain vasculature in signaling pathways that can potentially protect cells, as well as treatment options for the maintenance of cerebrovascular functioning to prevent diseases associated with brain vasculature remodeling in response to aging and associated diseases and present new treatment options.

Guest Editor

Prof. Dr. Aurel Popa-Wagner

1. Chair of Vascular Neurology and Dementia, Essen University Medical School, Essen, Germany
2. Experimental Research Center for Normal and Pathological Aging Director, University of Medicine and Pharmacy of Craiova, Craiova, Romania

Deadline for manuscript submissions

closed (30 November 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/123356

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).